GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CNBX Pharmaceuticals CNBX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About CNBX Pharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

CNBX Pharmaceuticals is based in Bethesda, Maryland and is incorporated in Nevada. Its shares trade on OTC under the ticker CNBX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 August 2025, it reported revenue of $0 and a net loss of $313,976. At that date it held total assets of $18,437 and shareholders' equity of −$2.5m.

In its own words

Corporation, purchased 20,500,000 shares of restricted stock of the Company, thus acquiring control of the Company.

Inc. incorporated a wholly owned subsidiary in Israel, named “G.R.I.N Ultra Ltd”, dedicated to advanced research and development.

Sourasky Medical Center in Tel-Aviv, Israel, where he is head of the Endoscopic Submucosal Dissection (ESD) program.

On May 12, 2022, the Company effected a reverse-split of its common stock on a 1:120 basis.

We believe, therefore, that cannabinoid combinations may hold promise for an improved anti-proliferative strategy for cancer management.

1,392,445people living with CRC in 2021(Source: National Cancer Institute. “Cancer Stat Facts: Colorectal Cancer”).

According to the American Cancer Society, an estimated one-third to one-half of all individuals will eventually develop one or more adenomas.

Quoted from its 10-K, filed 1 Dec 2025. Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
2 Jul 2007
Employees
9
Head office
#3 BETHESDA METRO CENTER, BETHESDA, MD, 20814
Incorporated in
NV
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Gabriel YarivExecutive Chairman of the Board, since 2019$188,027
  • Mr. Eyal BaradChief Executive Officer, Director, since 2017$200,532
  • Mr. Uri Ben-OrChief Financial Officer$33,968
  • Dr. Sanja GoldbergChief Technology Officer

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company employs 9 full-time employees.
  • Headquartered in Bethesda, Maryland.
  • Develops cannabinoid-based treatments and therapies.

Weaknesses

  • Company has not generated revenues.
  • IPO occurred in 2007-07-02.
  • Early stage biotechnology company.

Opportunities

  • Development of personalized anti-cancer treatments.
  • Licensing of cannabinoid-based therapies.
  • Expansion of delivery systems for cannabinoids.

Threats

  • Untrusted source description of company activities.
  • No revenue generation indicates financial instability.
  • Early stage company faces high development risks.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.